Overview
ALEBUND-B (9637)
Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China a...
- Open
- 20.600
- High
- 20.880
- Low
- 19.810
- Prev. Close
- 20.600
- Volume
- 449.80K
- Turnover
- 9.06M
- Avg Price
- 20.146
- Bid/Ask Ratio
- 33.33%
- Amplitude
- 5.19%
- 52wk High
- 46.820
- Volume Ratio
- 2.22
- Turnover Ratio
- 0.22%
- 52wk Low
- 14.360
- HK Mkt Cap
- 4.16B
- Market CapHKD
- 6.99B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -2.33
- EPSDynamic
- -1.08
- EPSStatic
- --
- BVPS
- 4.66
- P/B
- 4.31
- HK Shares
- 206.96M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 347.95M
- Min lot size
- 100
- Currency
- HKD
ALEBUND-B Analyst Rating
View moreForecast & Rating
Sep 23, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 3
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 13
Alebund Pharmaceuticals (9637.HK) closed at HK$20.60, down 2.9% from the prior HK$21.22, tracing a dip-and-recover shape: an early push to HK$21.20 gave way to a morning-session low of HK$19.39 at 10:35 BJ, before afternoon buying lifted the stock back to HK$20.80, with 602,800 shares traded for HK$12.2 million and a turnover rate of only 0.31%. Repeated next-day disclosure returns on share buybacks over recent sessions have not reversed the drift. Q2 2026 revenue reached HK$60.15 million, up 806.48% year on year, while the net loss of HK$93.88 million narrowed 17.93% yoy, net margin at -156.06% and EPS at -HK$0.3309; partner R1 also presented the Phase IIb trial design for AP306 in hyperphosphatemia. The stock is 55.22% lower year to date and 56% below its 52-week high of HK$46.82 set on its 29 June listing, above the MA20 of HK$17.78 but below the MA60 of HK$23.90, with PB at 4.42. Though the afternoon rebound from HK$19.39 to HK$20.80 points to some support at the low.
- Nov, 11
Alebund Pharmaceuticals reversed an early dip to close at HK$21.00, up 5.00% from the prior HK$20.00 close, after touching HK$19.90 at 11:18 BJ and then grinding to an intraday high of HK$21.00 at 15:57; the afternoon session carried 368,700 of the 419,900 shares traded, with a run of next-day disclosure returns announcing share buybacks over the past week acting as the main driver. Q2 2026 revenue reached HK$60.15m, up 806.48% year on year, while the net loss narrowed 17.93% to HK$93.88m and EPS improved 34.18% to -HK$0.3309, though net margin stayed at -156.06%. The stock sits above its MA20 of HK$17.72 but far below MA60 of HK$24.33, down 54.35% year to date and 55.15% below its HK$46.82 listing-day high, yet 46.24% above the HK$14.36 low of 22 October, with PB at 4.51x. The company remains loss-making, and a 0.20% turnover rate suggests buyback and trading volumes are modest against a HK$7.31bn market value.
- Nov, 6
ALEBUND-B (9637.HK) opened at HK$18.00, dipped to that level at 09:32 BJ, then climbed to an intraday HK$19.37 by 10:13 and settled at HK$19.18, up 3.84% from the prior close of HK$18.47 on HK$12.56 million turnover. The bid followed four straight sessions of repurchases, including 74,100 shares for HK$1.2485 million on Nov 4 under a HK$100 million H-share buyback programme, while partner R1 presented the global Phase IIb multi-regional trial design poster for AP306 at ASN Kidney Week. Q2 2026 revenue reached HK$60.15 million, up 806.48% year on year, with the net loss narrowing 17.93% to HK$93.88 million and net margin still at -156.06%. The price sits above its MA20 of HK$18.36 but below MA60 of HK$25.00, down 58.30% year to date and 59.03% below the 52-week high of HK$46.82. Though a 4.12x price-to-book and negative PE leave profitability unproven.
- Nov, 5
Alebund-B reversed early weakness to close up 6.15% at HK$18.47, supported by its ongoing HK$100 million buyback and partner R1's poster of the AP306 global Phase IIb multi-regional trial design at ASN Kidney Week. The morning session slid from HK$17.80 to HK$17.42; the afternoon dipped to HK$17.36 at 13:12 BJ before rallying to HK$18.70 at 14:01 and settling at HK$18.47 on 1.03 million shares and HK$18.71 million turnover. Buybacks ran at 58,300 shares on Nov 2, 12,200 on Nov 3 and 74,100 on Nov 4, for HK$995,900, HK$200,200 and HK$1,248,500 respectively. Q2 2026 revenue reached HK$60.15 million, up 806.48% year on year, while the net loss narrowed 17.93% to HK$93.88 million and EPS improved 34.18%. The stock is still down 59.85% year to date and 60.55% below its 52-week high of HK$46.82, with the HK$18.47 close just under the MA20 of HK$18.745 and far below the MA60 of HK$25.28. Though a 3.97 price-to-book and negative PE indicate profitability has not yet turned positive.
- Nov, 4
Alebund Pharmaceuticals-B rebounded from its morning trough and finished at the session high of HK$17.400, up 5.39% from HK$16.510, after sliding to HK$15.650 at 11:08 in the morning session and climbing through the afternoon to that 15:59 print. The move followed execution of the buyback: under a HK$100 million H-share repurchase plan, the company spent HK$995,900 on 58,300 shares on 2 November and HK$200,200 on 12,200 shares on 3 November, while partner R1 presented the global Phase IIb design for AP306 at ASN Kidney Week and AP308 received FDA clinical clearance. Q2 2026 revenue of HK$60.15 million grew 806% year on year and the net loss of HK$93.88 million narrowed 17.9%, though net margin stayed at -156%. The stock remains 62.8% below its 52-week high of HK$46.82 and down 62.2% year to date, trading under its MA20 of HK$19.25; while market value is about HK$6.06 billion and PE is -7.48, profit has not turned positive and the repurchase is still small relative to market cap.
News
PUBT · Alebund Pharmaceuticals Files HKEX Next-Day Return Disclosing Share Buyback
PUBT · Alebund Pharmaceuticals Reports Share Buyback in HKEX Next-Day Disclosure Return
Market Movers · Alebund falls nearly 7% in Hong Kong trading
PUBT · Alebund Pharmaceuticals Discloses Share Buyback in HKEX Next-Day Return
Market Movers · Alebund climbs 6%
PUBT · Alebund Pharmaceuticals files next-day disclosure return with HKEX announcing share buyback
